PANK4 and glioblastoma: To assess whether the phosphatase activity of PANK4 is required for its ability to modulate sensitivity to TMZ treatment, we overexpressed the wild‐type and two phosphatase‐dead mutants (D623A and D659A) of PANK4 in our TMZ‐resistant GBM cells.